title: On the Biological Importance of the 3-hydroxyanthranilic Acid: Anthranilic Acid Ratio.
abstract: Of the major components of the kynurenine pathway for the oxidative metabolism of tryptophan, most attention has focussed on the N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid, and the glutamate receptor blocker kynurenic acid. However, there is increasing evidence that the redox-active compound 3-hydroxyanthranilic acid may also have potent actions on cell function in the nervous and immune systems, and recent clinical data show marked changes in the levels of this compound, associated with changes in anthranilic acid levels, in patients with a range of neurological and other disorders including osteoporosis, chronic brain injury, Huntington's disease, coronary heart disease, thoracic disease, stroke and depression. In most cases, there is a decrease in 3-hydroxyanthranilic acid levels and an increase in anthranilic acid levels. In this paper, we summarise the range of data obtained to date, and hypothesise that the levels of 3-hydroxyanthranilic acid or the ratio of 3-hydroxyanthranilic acid to anthranilic acid levels, may contribute to disorders with an inflammatory component, and may represent a novel marker for the assessment of inflammation and its progression. Data are presented which suggest that the ratio between these two compounds is not a simple determinant of neuronal viability. Finally, a hypothesis is presented to account for the development of the observed changes in 3-hydroxyanthranilic acid and anthranilate levels in inflammation and it is suggested that the change of the 3HAA:AA ratio, particularly in the brain, could possibly be a protective response to limit primary and secondary damage.
authors.affiliation: Epsom General Hospital, Dorking Road, Epsom, Surrey KT18 7EG, UK.
authors.forename: L Gail
authors.initials: LG
authors.lastname: Darlington
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Forrest
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Mackay
authors.forename: Robert A
authors.initials: RA
authors.lastname: Smith
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Smith
authors.forename: Nicholas
authors.initials: N
authors.lastname: Stoy
authors.forename: Trevor W
authors.initials: TW
authors.lastname: Stone
references.citation: Biochem J. 1953 Mar;53(4):513-21
references.pmid: 13032103
references.citation: Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1078-87
references.pmid: 17042918
references.citation: Biochem Biophys Res Commun. 2003 Jan 17;300(3):719-24
references.pmid: 12507509
references.citation: J Neurosci. 2007 Nov 21;27(47):12884-92
references.pmid: 18032661
references.citation: Inflamm Res. 2005 Sep;54(9):390-3
references.pmid: 16273338
references.citation: Eur J Pharmacol. 2009 Mar 15;606(1-3):225-32
references.pmid: 19374879
references.citation: Arch Biochem Biophys. 1997 Apr 1;340(1):117-23
references.pmid: 9126284
references.citation: Plant Physiol. 1996 Jul;111(3):893-900
references.pmid: 12226335
references.citation: J Pharmacol Exp Ther. 2002 Oct;303(1):1-10
references.pmid: 12235226
references.citation: Biochem Pharmacol. 1987 Jan 15;36(2):211-7
references.pmid: 2949752
references.citation: Arch Biochem Biophys. 1990 Jan;276(1):248-50
references.pmid: 2404453
references.citation: Immunol Lett. 2008 Apr 15;117(1):91-5
references.pmid: 18289708
references.citation: Mol Immunol. 2006 Jul;43(14):2151-60
references.pmid: 16490253
references.citation: Adv Exp Med Biol. 1991;294:485-8
references.pmid: 1772081
references.citation: Eur J Neurol. 2006 Jan;13(1):30-42
references.pmid: 16420391
references.citation: Cell Death Differ. 2002 Oct;9(10):1069-77
references.pmid: 12232795
references.citation: J Neurochem. 2005 May;93(3):611-23
references.pmid: 15836620
references.citation: Neurochem Int. 2007 Jan;50(1):83-94
references.pmid: 16959377
references.citation: Biochemistry. 2000 Jun 20;39(24):7266-75
references.pmid: 10852726
references.citation: Metabolism. 1999 Dec;48(12):1608-11
references.pmid: 10599996
references.citation: Eur J Pharmacol. 1981 Jul 10;72(4):411-2
references.pmid: 6268428
references.citation: Neurotox Res. 2009 May;15(4):303-10
references.pmid: 19384564
references.citation: Science. 1939 Apr 21;89(2312):368-70
references.pmid: 17833351
references.citation: Atherosclerosis. 2006 Aug;187(2):274-84
references.pmid: 16246346
references.citation: Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18619-24
references.pmid: 18003900
references.citation: Clin Exp Pharmacol Physiol. 2009 Apr;36(4):425-35
references.pmid: 19018805
references.citation: Nat Rev Drug Discov. 2002 Aug;1(8):609-20
references.pmid: 12402501
references.citation: J Biol Chem. 1959 May;234(5):1191-4
references.pmid: 13654345
references.citation: Biochem Biophys Res Commun. 2004 Aug 6;320(4):1156-62
references.pmid: 15249210
references.citation: Neurosci Res. 2009 May;64(1):111-7
references.pmid: 19428689
references.citation: Eur J Pharmacol. 1988 Sep 1;154(1):85-7
references.pmid: 2846328
references.citation: Eur J Pharmacol. 1999 Jun 30;375(1-3):87-100
references.pmid: 10443567
references.citation: J Neurochem. 2010 Jan;112(1):112-22
references.pmid: 19845828
references.citation: Biochem J. 1988 May 1;251(3):893-9
references.pmid: 2843167
references.citation: Prog Neurobiol. 2001 Jun;64(2):185-218
references.pmid: 11240212
references.citation: Brain Res. 1982 Sep 9;247(1):184-7
references.pmid: 6215086
references.citation: J Neurochem. 1998 Jan;70(1):299-307
references.pmid: 9422375
references.citation: Infect Immun. 2005 Aug;73(8):5249-51
references.pmid: 16041050
references.citation: Eur J Neurosci. 2007 Oct;26(8):2211-21
references.pmid: 17892481
references.citation: Brain Res. 2006 Feb 16;1073-1074:25-37
references.pmid: 16448631
references.citation: J Biol Chem. 1962 Jul;237:2318-24
references.pmid: 13925604
references.citation: Ann Clin Biochem. 2001 May;38(Pt 3):242-51
references.pmid: 11392499